Aromatase inhibition by 2-methyl indole hydrazone derivatives evaluated via molecular docking and in vitro activity studies

References

• Ahmad IS. (2015). Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer. Eur J Med Chem 102:375–86.
   PubMed Web of Science ®Google Scholar
• Alvarez-García V, González A, Martínez-Campa C, et al. (2013). Melatonin modulates aromatase activity and expression in endothelial cells. Oncol Rep 29:2058–64.
   PubMed Web of Science ®Google Scholar
• Baravalle R, Ciaramella A, Baj F, et al. (2018). Identification of endocrine disrupting chemicals acting on human aromatase. Biochim Biophys Acta (BBA) – Proteins Proteom 1866:88–96.
   PubMed Web of Science ®Google Scholar
• Briest S, Davidson NE. (2007). Aromatase inhibitors for breast cancer. Rev Endocr Metab Disord 8:215–28.
   PubMed Web of Science ®Google Scholar
• Brueggemeier RW, Hackett JC, Diaz-Cruz ES. (2005). Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26:331–45.
   PubMed Web of Science ®Google Scholar
• Cheshenko K, Pakdel F, Segner H, et al. (2008). Interference of endocrine disrupting chemicals with aromatase CYP19 expression or activity, and consequences for reproduction of teleost fish. General Comp Endocrinol 155:31–62.
   PubMed Web of Science ®Google Scholar
• Chottanapund S, Van Duursen MBM, Navasumrit P, et al. (2014). Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts. Toxicol In vitro Int J pub assoc BIBRA 28:1215–21.
   PubMed Web of Science ®Google Scholar
• Cos S, González A, Güezmes A, et al. (2006). Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118:274–8.
   PubMed Web of Science ®Google Scholar
• Cos S, Martinez-Campa C, Mediavilla MD, Sanchez-Barcelo EJ. (2005). Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 38:136–42.
   PubMed Web of Science ®Google Scholar
• Cos S, Sánchez-Barceló EJ. (1995). Melatonin inhibition of MCF-7 human breast-cancer cells growth: influence of cell proliferation rate. Cancer Lett 93:207–12.
   PubMed Web of Science ®Google Scholar
• Davis EC, Popper P, Gorski RA. (1996). The role of apoptosis in sexual differentiation of the rat sexually dimorphic nucleus of the preoptic area. Brain Res 734:10–8.
   PubMed Web of Science ®Google Scholar
• Furr BJA. (2006). Milestones in drug therapy, aromatase inhibitors. Basel, Switzerland: Birkha¨user, p.182
   Google Scholar
• Ghosh D, Lo J, Egbuta C. (2016). Recent progress in the discovery of next generation inhibitors of aromatase from the structure- function perspective. J Med Chem 59:5131–48.
   PubMed Web of Science ®Google Scholar
• Ghosh D, Griswold J, Erman M, Pangborn W. (2009). Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 457:219–23.
   PubMed Web of Science ®Google Scholar
• González-González A, Mediavilla MD, Sánchez BEJ. (2018). Melatonin: a molecule for reducing breast cancer risk. Molecules (Basel, Switzerland) 23: 336.
   PubMed Web of Science ®Google Scholar
• Gurer-Orhan H, Ince E, Konyar D, et al. (2017). The role of oxidative stress modulators in breast cancer. Curr Med Chem 24.
   Web of Science ®Google Scholar
• Gurer-Orhan H, Karaaslan C, Ozcan S, et al. (2016). Novel indole-based melatonin analogues: Evaluation of antioxidant activity and protective effect against amyloid β-induced damage. Bioorganic Med Chem 24:1658–64.
   PubMed Web of Science ®Google Scholar
• Gurer-Orhan H, Suzen S. (2015). Melatonin, its metabolites and its synthetic analogs as multi-faceted compounds: antioxidant, prooxidant and inhibitor of bioactivation reactions. Curr Med Chem 22:490–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25515518. [last accessed: 27 Feb 2017].
   PubMed Web of Science ®Google Scholar
• Hill SM, Blask DE. (1988). Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48: 6121–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3167858 [last accessed 20 Feb 2018].
   PubMed Web of Science ®Google Scholar
• Kang H, Xiao X, Huang C, et al. (2018). Potent aromatase inhibitors and molecular mechanism of inhibitory action. Eur J Med Chem 143:426–37.
   PubMed Web of Science ®Google Scholar
• Labute P. (2009). Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins 75:187–205.
   PubMed Web of Science ®Google Scholar
• Martínez-Campa C, González A, Mediavilla MD, et al. (2009). Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Brit J Cancer 101:1613–9.
   PubMed Web of Science ®Google Scholar
• Di Nardo G, Breitner M, Bandino A, et al. (2015). Evidence for an elevated aspartates pK(a) in the active site of human aromatase. J Biol Chem 290:1186–96.
   PubMed Web of Science ®Google Scholar
• Di Nardo G, Gilardi G. (2013). Human aromatase: perspectives in biochemistry and biotechnology. Biotechnol Appl Biochem 60:92–101.
   PubMed Web of Science ®Google Scholar
• Pingaew R, Mandi P, Prachayasittikul V, et al. (2018). Synthesis, molecular docking, and QSAR study of sulfonamide-based indoles as aromatase inhibitors. Eur J Med Chem 143:1604–15.
   PubMed Web of Science ®Google Scholar
• Saldanha CJ, Duncan KA, Walters BJ. (2009). Neuroprotective actions of brain aromatase. Front Neuroendocrinol 30:106–18.
   PubMed Web of Science ®Google Scholar
• Sanchez-Barcelo EJ, M-C, CM., Mediavilla MD, Gonzalez A, et al. (2007). Melatonin and melatoninergic drugs as therapeutic agents: ramelteon and agomelatine, the two most promising melatonin receptor agonists. Recent Pat Endocr Metab Immune Drug Discov, 142–51.
   Google Scholar
• Sanderson JT. (2006). The steroid hormone biosynthesis pathway as a target for endocrine-disrupting chemicals. Toxicol Sci 94:3–21.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Brodie H, Simpson ER, et al. (2009). History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 30:343–75.
   PubMed Web of Science ®Google Scholar
• Schernhammer ES, Laden F, Speizer FE, et al. (2001). Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Nat Cancer Instit 93:1563–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11604480 [last accessed: 20 Feb 2018].
   PubMed Web of Science ®Google Scholar
• Suzen S. (2015). Evaluation of synthetic melatonin analogue antioxidant compounds. In: Srinivasan V, Gobbi G, Shillcutt S.D, Suzen S, eds. Melatonin: therapeutic value and neuroprotection. Boca Raton, FL: Taylor & Francis, Chapter 21, 259–69. ISBN: 9781482220100 1482220105
   Google Scholar
• Suzen S, Tekiner-Gulbas B, Shirinzadeh H, et al. (2013). Antioxidant activity of indole-based melatonin analogues in erythrocytes and their voltammetric characterization. J Enzyme Inhib Med Chem 28:1143–55.
   PubMed Web of Science ®Google Scholar
• Wang R, Shi H-F, Zhao J-F, et al. (2013). Design, synthesis and aromatase inhibitory activities of novel indole-imidazole derivatives. Bioorganic Med Chem Lett 23:1760–2.
   PubMed Web of Science ®Google Scholar
• Whitehead SA, Rice S. (2006). Endocrine-disrupting chemicals as modulators of sex steroid synthesis. Best Pract Res Clin Endocrinol Metabol 20:45–61.
   PubMed Web of Science ®Google Scholar